-
The critical role of exercise in the GLP-1 era
As GLP-1 receptor agonists reshape obesity treatment, a new medical perspective published in JAMA, underscores a persistent gap in care:... Read more -
Gut hormone FGF15 changes how mice respond to weight loss
Nearly 40% of the population in the United States develop obesity, which is linked to the development of several diseases,... Read more -
Obesity and Alzheimer's linked by disease-driving metabolic pathways
By 2030, the population in the United States aged 65 and older is expected to reach 71 million or about... Read more -
Most severe obesity still goes untreated as GLP-1 use climbs and surgery slips
Drawing on electronic health records from nearly 20 million patients with severe obesity, researchers from University of California San Diego... Read more -
Bariatric surgery procedures fall below 200,000, first time since 2020, new research finds
The number of metabolic and bariatric surgery procedures in the United States dropped below 200,000 in 2024 for the first... Read more -
Bariatric surgery slashes risk of kidney failure, heart attack and death, new data show
Metabolic and bariatric surgery, also known as weight-loss surgery, dramatically improves outcomes for patients with obesity and chronic kidney disease... Read more -
Metabolic and bariatric surgery after GLP-1 treatment significantly boosts weight loss, research finds
People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery achieve substantially... Read more -
The GLP-1 paradox: Weight loss drugs may lead to stigma
Glucagonlike peptide-1 (GLP-1) medications have taken over the national conversation around weight loss. From celebrity headlines to everyday conversations, GLP-1... Read more -
Managing weight may slow brain aging within two years, 24-year data suggest
Being overweight may lead to accelerated cognitive decline, according to new research from the University of Georgia. The paper is... Read more -
Stopping and restarting certain GLP-1s to lose weight may make the drug less effective
Inconsistent use of some GLP-1 weight-loss medications, like Ozempic and Wegovy, may significantly lessen their effectiveness, according to a new... Read more -
Scientists cautiously suggest GLP-1s are safe to use around pregnancy
A new study from the University of St Andrews suggests weight-loss drugs like Ozempic taken around pregnancy do not raise... Read more -
How unhealthy ultra‑processed foods are designed and marketed to make us crave them
Consumption of ultra-processed foods—including soft drinks, snacks and ready meals—is growing worldwide, despite evidence they are unhealthy.... Read more -
Two people, same weight, vastly different futures: New tool exposes obesity danger before disease strikes
The study, published in Nature Medicine, shows that future risk of 18 obesity-related diseases can be predicted using 20 commonly... Read more -
Wearable glucose monitors offer real‑time data, but for healthy people no guidelines exist to interpret the numbers
Keeping tabs on blood sugar throughout the day used to be the exclusive domain of people with diabetes. But in... Read more -
Centers for Medicare & Medicaid Services extends short-term bridge program for GLP-1 obesity drug coverage
The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity... Read more
